295 related articles for article (PubMed ID: 25145931)
21. Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion.
Hofmann U; Hu K; Walter F; Burkard N; Ertl G; Bauersachs J; Ritter O; Frantz S; Bonz A
Br J Pharmacol; 2010 Jul; 160(5):1243-51. PubMed ID: 20590616
[TBL] [Abstract][Full Text] [Related]
22. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity.
Sawicka E; Dubois G; Jarai G; Edwards M; Thomas M; Nicholls A; Albert R; Newson C; Brinkmann V; Walker C
J Immunol; 2005 Dec; 175(12):7973-80. PubMed ID: 16339533
[TBL] [Abstract][Full Text] [Related]
23. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
[TBL] [Abstract][Full Text] [Related]
24. Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells.
Liu G; Bi Y; Wang R; Yang H; Zhang Y; Wang X; Liu H; Lu Y; Zhang Z; Chen W; Chu Y; Yang R
J Immunol; 2014 Apr; 192(7):3068-79. PubMed ID: 24567529
[TBL] [Abstract][Full Text] [Related]
25. Prominence of central sphingosine-1-phosphate receptor-1 in attenuating aβ-induced injury by fingolimod.
Asle-Rousta M; Kolahdooz Z; Dargahi L; Ahmadiani A; Nasoohi S
J Mol Neurosci; 2014 Dec; 54(4):698-703. PubMed ID: 25239520
[TBL] [Abstract][Full Text] [Related]
26. FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration.
Hwang SJ; Kim JH; Kim HY; Kim S; Chung DH
Lab Invest; 2010 Jan; 90(1):9-19. PubMed ID: 19823172
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
28. FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2.
Valentine WJ; Godwin VI; Osborne DA; Liu J; Fujiwara Y; Van Brocklyn J; Bittman R; Parrill AL; Tigyi G
J Biol Chem; 2011 Sep; 286(35):30513-30525. PubMed ID: 21719706
[TBL] [Abstract][Full Text] [Related]
29. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T; Billich A; Brinkmann V
Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
[TBL] [Abstract][Full Text] [Related]
30. Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P.
Kohno T; Igarashi Y
Genes Cells; 2008 Jul; 13(7):747-57. PubMed ID: 18513330
[TBL] [Abstract][Full Text] [Related]
31. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes.
Singer II; Tian M; Wickham LA; Lin J; Matheravidathu SS; Forrest MJ; Mandala S; Quackenbush EJ
J Immunol; 2005 Dec; 175(11):7151-61. PubMed ID: 16301618
[TBL] [Abstract][Full Text] [Related]
32. Selective Sphingosine 1-Phosphate Receptor 1 Agonist Is Protective Against Ischemia/Reperfusion in Mice.
Brait VH; Tarrasón G; Gavaldà A; Godessart N; Planas AM
Stroke; 2016 Dec; 47(12):3053-3056. PubMed ID: 27827329
[TBL] [Abstract][Full Text] [Related]
33. [Immunosuppressive effect of S1P1 receptor agonist FTY720].
Zhou WQ; Zhang HJ; Jin J; Li Y; Li C; Chen XG
Yao Xue Xue Bao; 2012 Apr; 47(4):546-50. PubMed ID: 22799042
[TBL] [Abstract][Full Text] [Related]
34. Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis.
Awojoodu AO; Ogle ME; Sefcik LS; Bowers DT; Martin K; Brayman KL; Lynch KR; Peirce-Cottler SM; Botchwey E
Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13785-90. PubMed ID: 23918395
[TBL] [Abstract][Full Text] [Related]
35. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
36. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling.
Egom EE; Ke Y; Musa H; Mohamed TM; Wang T; Cartwright E; Solaro RJ; Lei M
J Mol Cell Cardiol; 2010 Feb; 48(2):406-14. PubMed ID: 19852968
[TBL] [Abstract][Full Text] [Related]
37. [Effects of sphingosine 1-phosphate on functions of T cell - review].
Huang WR; Wang LS; DA WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):718-22. PubMed ID: 16129068
[TBL] [Abstract][Full Text] [Related]
38. FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms.
Norimatsu Y; Ohmori T; Kimura A; Madoiwa S; Mimuro J; Seichi A; Yatomi Y; Hoshino Y; Sakata Y
Am J Pathol; 2012 Apr; 180(4):1625-35. PubMed ID: 22417787
[TBL] [Abstract][Full Text] [Related]
39. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
40. Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction.
Thangada S; Shapiro LH; Silva C; Yamase H; Hla T; Ferrer FA
J Urol; 2014 May; 191(5 Suppl):1508-16. PubMed ID: 24679864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
